This site is intended for US healthcare professionals.

A new treatment is on its way

BICTEGRAVIR (75 mg) LENACAPAVIR (50 mg)

A fixed-dose combination tablet

Register to receive updates about this treatment and other related topics

*Required field

First name

Last name

Email address Confirm Email

NPI #

I certify that I am a US healthcare professional 18 years of age or older.

To learn more about how Gilead may use your information, please see our Global Privacy Statement and US Healthcare Professional Privacy Notice.

Privacy Policy
Consumer Health Data Privacy Policy
Terms of Use
Contact Us
Site Map
Your Privacy Choices

The information contained on this site is intended for healthcare provider audiences in the United States only. The content on this site may not apply to non-US audiences as regulatory control, legal requirements, and/or medical practices may vary in other countries.

GILEAD and the GILEAD Logo are trademarks of Gilead Sciences, Inc., or its related companies. All other marks are the property of their respective owners.

© 2026 Gilead Sciences, Inc. All rights reserved. US-UNBP-4336 05/26